EVALUATION OF TRIACETYLOLEANDOMYCIN, ALPHA-NAPHTHOFLAVONE AND DIETHYLDITHIOCARBAMATE AS SELECTIVE CHEMICAL PROBES FOR INHIBITION OF HUMAN CYTOCHROMES P450

被引:268
作者
CHANG, TKH
GONZALEZ, FJ
WAXMAN, DJ
机构
[1] HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA
[2] HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA
[3] NCI, MOLEC CARCINOGENESIS LAB, BETHESDA, MD 20892 USA
关键词
D O I
10.1006/abbi.1994.1259
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
A variety of chemicals, including triacetyloleandomycin (TAO), alpha-naphthoflavone (ANF), and diethyldithiocarbamate (DDC), are widely used as inhibitory probes for select individual human cytochrome P450 (CYP) enzymes, despite the fact that the selectivity of these inhibitors has not been rigorously evaluated. In the present study we take advantage of recent advances in cDNA-directed human P450 expression to evaluate directly the P450 form selectivity of TAO, ANF, and DDC, using a panel of 10 individual cDNA-expressed human P450s. Under experimental conditions known to yield maximal TAO complexation with P450 hemoproteins, TAO (20 mu M) inhibited the catalytic activity of expressed CYPs 3A3, 3A4, and 3A5, whereas it did not affect CYPs 1A1, 1A2, 2A6, 2B6, 2C8, 2C9, or 2E1 activity. ANF inhibited not only CYPs 1A1 and 1A2 (IC50 = 0.4-0.5 mu M), but it was also similarly effective against CYPs 2C8 and 2C9. Increasing the concentration of ANF to 10 mu M led to inhibition of CYP2A6 and CYP2B6. Although a previous study suggested that DDC is a selective inhibitor of CYP2E1, the present investigation shows that at concentrations required to inhibit CYP2E1 (IC50 approximate to 125 mu M when preincubated with NADPH), DDC also inhibited CYPs 1A1, 1A2, 2A6, 2B6, 2C8, 3A3, and 3A4. Decreasing the concentration of DDC to 10 mu M, however, led to inhibition of CYP2A6 (65% inhibition) and CYP2B6 (50% inhibition), but none of the other p450s examined, including CYP2E1. Overall, these results establish that (a) TAO is a selective inhibitor of the human CYP3A subfamily; (b) ANF potently inhibits CYP2C8 and CYP2C9, in addition to CYPs 1A1 and 1A2; and (c) DDC cannot be employed as a diagnostic inhibitory probe for CYP2E1. (C) 1994 Academic Press, Inc.
引用
收藏
页码:437 / 442
页数:6
相关论文
共 46 条
[1]
INHIBITION OF ELIMINATION OF CAFFEINE BY DISULFIRAM IN NORMAL SUBJECTS AND RECOVERING ALCOHOLICS [J].
BEACH, CA ;
MAYS, DC ;
GUILER, RC ;
JACOBER, CH ;
GERBER, N .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 39 (03) :265-270
[2]
CATALYTIC ACTIVITIES OF HUMAN LIVER CYTOCHROME-P-450-IIIA4 EXPRESSED IN SACCHAROMYCES-CEREVISIAE [J].
BRIAN, WR ;
SARI, MA ;
IWASAKI, M ;
SHIMADA, T ;
KAMINSKY, LS ;
GUENGERICH, FP .
BIOCHEMISTRY, 1990, 29 (51) :11280-11292
[3]
HUMAN CYTOCHROME P-450PA (P-450IA2), THE PHENACETIN O-DEETHYLASE, IS PRIMARILY RESPONSIBLE FOR THE HEPATIC 3-DEMETHYLATION OF CAFFEINE AND N-OXIDATION OF CARCINOGENIC ARYLAMINES - (AROMATIC-AMINES HETEROCYCLIC AMINES CARCINOGEN METABOLISM) [J].
BUTLER, MA ;
IWASAKI, M ;
GUENGERICH, FP ;
KADLUBAR, FF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (20) :7696-7700
[4]
HIGH VARIABILITY OF NITROSAMINE METABOLISM AMONG INDIVIDUALS - ROLE OF CYTOCHROMES P450 2A6 AND 2E1 IN THE DEALKYLATION OF N-NITROSODIMETHYLAMINE AND N-NITROSODIETHYLAMINE IN MICE AND HUMANS [J].
CAMUS, AM ;
GENESTE, O ;
HONKAKOSKI, P ;
BEREZIAT, JC ;
HENDERSON, CJ ;
WOLF, CR ;
BARTSCH, H ;
LANG, MA .
MOLECULAR CARCINOGENESIS, 1993, 7 (04) :268-275
[5]
CHANG TKH, 1993, CANCER RES, V53, P5629
[6]
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[7]
TRANSFECTION OF A HUMAN CYTOCHROME-P-450 GENE INTO THE HUMAN-LYMPHOBLASTOID CELL-LINE, AHH-1, AND USE OF THE RECOMBINANT CELL-LINE IN GENE MUTATION ASSAYS [J].
CRESPI, CL ;
LANGENBACH, R ;
RUDO, K ;
CHEN, YT ;
DAVIES, RL .
CARCINOGENESIS, 1989, 10 (02) :295-301
[8]
RELATIONSHIP BETWEEN PHENYTOIN AND TOLBUTAMIDE HYDROXYLATIONS IN HUMAN LIVER-MICROSOMES [J].
DOECKE, CJ ;
VERONESE, ME ;
POND, SM ;
MINERS, JO ;
BIRKETT, DJ ;
SANSOM, LN ;
MCMANUS, ME .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (02) :125-130
[9]
EUGSTER HP, 1993, DRUG METAB DISPOS, V21, P43
[10]
INHIBITION OF MIXED-FUNCTION OXIDATIONS BY SUBSTRATES FORMING REDUCED CYTOCHROME-P-450 METABOLIC-INTERMEDIATE COMPLEXES [J].
FRANKLIN, MR .
PHARMACOLOGY & THERAPEUTICS PART A-CHEMOTHERAPY TOXICOLOGY AND METABOLIC INHIBITORS, 1977, 2 (01) :227-245